Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems
arXiv:2512.13724v1 Announce Type: cross Abstract: Neurological diseases are the leading global cause of disability, yet most lack disease-modifying treatments. We present PROTON, a heterogeneous graph transformer that generates testable hypotheses across molecular, organoid, and clinical systems. To evaluate PROTON, we apply it to Parkinson's disease (PD), bipolar disorder (BD), and Alzheimer's disease (AD). In PD, PROTON linked genetic risk loci to genes essential for dopaminergic neuron survi
-
cs.AI, q-bio.NC updates on arXiv.org
-
AI Deception: Risks, Dynamics, and Controls
arXiv:2511.22619v2 Announce Type: replace Abstract: As intelligence increases, so does its shadow. AI deception, in which systems induce false beliefs to secure self-beneficial outcomes, has evolved from a speculative concern to an empirically demonstrated risk across language models, AI agents, and emerging frontier systems. This project provides a comprehensive and up-to-date overview of the AI deception field, covering its core concepts, methodologies, genesis, and potential mitigations. Fir
AI Deception: Risks, Dynamics, and Controls
-
Omics In Lung
-
RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis
Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.ABSTRACTA user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognost
RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis
Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.
ABSTRACT
A user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognostic model using coxBoost + RSF algorithms in lung cancer highlighted m6A as a suitable marker to guide therapeutic strategy. RMethyMD provides a comprehensive resource and multiomics analysis to explore m6A-based prognostic and clinical values, thereby contributing to aiding personalized cancer therapy.
PMID:39809358 | DOI:10.1016/j.canlet.2025.217462
-
Oncogene - Issue - nature.com science feeds
-
Hypoxia switches TET1 from being tumor-suppressive to oncogenic
Oncogene, Published online: 05 April 2023; doi:10.1038/s41388-023-02659-wHypoxia switches TET1 from being tumor-suppressive to oncogenic
Hypoxia switches TET1 from being tumor-suppressive to oncogenic
Oncogene, Published online: 05 April 2023; doi:10.1038/s41388-023-02659-w
Hypoxia switches TET1 from being tumor-suppressive to oncogenic